相关实验视频

Updated: May 20, 2026

Using Retinal Imaging to Study Dementia

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

AlzheimerViT:利用轻量级视觉转换器架构进行主动性阿尔茨海默病查

C Kishor Kumar Reddy¹, Hafsa Ihteshamuddin Ahmed¹, Muhammad Mohzary^2,3

¹Department of Computer Science and Engineering, Stanley College of Engineering and Technology for Women, Hyderabad, India.

Frontiers in medicine

|July 2, 2025

概括

这项研究使用深度学习和MRI扫描来准确地早期检测阿尔茨海默病. 先进的视力转换器模型实现了98.57%的准确性,改善了诊断和患者的结果.

科学领域:

神经科学是一个神经科学.
医疗成像医学成像
人工智能的人工智能

背景情况:

阿尔茨海默病是一种进展性神经退行性疾病,其特点是记忆力丧失和认知能力下降.
早期发现和诊断阿尔茨海默氏症仍然具有挑战性,因为症状与正常衰老和其他认知障碍重叠.
磁共振成像 (MRI) 提供了详细的脑洞察力,对于识别与疾病相关的变化至关重要.

研究的目的:

利用MRI数据开发一个强大的深度学习模型,用于早期预测阿尔茨海默病.
通过数据预处理和增强来提高预测模型的概括性和性能.
研究先进的人工智能技术在阿尔茨海默病诊断中的临床适用性.

主要方法:

一个轻量级的,基于自我注意力的视觉转换器 (ViT) 模型被用于阿尔茨海默病的预测.
包含MRI图像的OASIS-3数据集被用于模型培训和验证.
实施了数据预处理和增强技术,以优化模型性能和通用化.
使用Grad-Cam可视化模型预测并了解特征的重要性.

主要成果:

拟议的ViT模型实现了98.57%的高诊断精度.
关键性能指标包括精度 (98.7%),回忆 (98.47%) 和特异性 (98.67%).
该模型表现出强的性能,卡帕得分为97.2%,AUC ROC得分为99%.

结论:

深度学习模型,特别是对MRI数据应用的ViT,显示出提高阿尔茨海默病诊断的巨大潜力.
全面的数据预处理和增强对于开发临床适用和可靠的预测模型至关重要.
通过人工智能改善早期检测可以导致及时干预,并为阿尔茨海默病患者提供更好的治疗结果.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.移动ViT 移动ViT 在线数据增强数据增强深度学习是一种深度学习.疾病检测检测疾病检测

更多相关视频

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...